NASDAQ
145.87USD
-0.31 (-0.21%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
9.4B
P/E
—
EPS
—
Beta
1.79
52W range
50.58-148
Day range
144.62–147.20
Open
146.18
Prev close
146.18
Volume
326.6K
Avg volume
708.1K
Dividend
0.00
IPO
2016-08-11
https://www.zacks.com/commentary/2951364/new-strong-buy-stocks-for-july-13th?cid=CS-STOCKNEWSAPI-FT-zacks_1_rank_additions-2951364 · 7/13/2026+1.00
https://seekingalpha.com/article/4914771-protagonist-therapeutics-a-royalty-driven-biotech-with-two-shots-on-goal · 6/13/2026+0.90
https://www.zacks.com/stock/news/2923448/j-j-s-pipeline-progress-new-drugs-promise-stronger-long-term-growth?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2923448 · 5/19/2026+0.80
https://www.zacks.com/stock/news/2890073/j-j-s-pipeline-surge-sets-up-stronger-growth-from-new-drugs-in-2026?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2890073 · 3/26/2026+1.00
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/correction-protagonist-reports-fourth-quarter-and-full-year-2025-fina-1141698 · 2/25/2026
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/protagonist-reports-fourth-quarter-and-full-year-2025-financial-resul-1141389 · 2/25/2026+0.80
https://www.businesswire.com/news/home/20251205962286/en/Protagonist-and-Takeda-Present-Longer-Term-Data-at-ASH-2025-Showing-Rusfertide-Delivers-Durable-Response-and-Hematocrit-Control-in-Polycythemia-Vera/ · 12/6/2025+0.80
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/protagonist-reports-third-quarter-2025-financial-results-and-provides-1097858 · 11/6/2025+0.90
https://www.zacks.com/stock/news/2767782/protagonist-therapeutics-stock-gains-30-as-j-j-reportedly-eyes-deal?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2767782 · 10/13/2025+1.00
https://seekingalpha.com/article/4829332-johnson-and-johnson-to-acquire-protagonist-itd-be-good-deal-to-make · 10/12/2025+0.90
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
